Wistar Institute enters agreement with Christiana Care Graham Cancer Center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

THE WISTAR INSTITUTE has entered into an agreement with the Gene Editing Institute at Christiana Care’s Helen F. Graham Cancer Center & Research Institute, expanding their previous partnership established in 2011.

The Gene Editing Institute will be integrated into Wistar’s Molecular Screening Facility. The Gene Editing Institute will retain its management structure and will remain located at the Graham Cancer Center on the Christiana Hospital Campus in Newark, Del. The Molecular Screening Facility will remain housed at Wistar in Philadelphia. According to the two organizations, they have already begun scientific collaborations involving research on melanoma and lung cancer. The previous partnership was the first inter-institutional affiliation between an NCI-designated basic research institution and a community cancer center.

YOU MAY BE INTERESTED IN

For decades, we have faced a central challenge in colorectal cancer screening. One in three eligible Americans—over 50 million people—remain unscreened despite established methods like colonoscopy or stool-based tests existing for decades. This gap persists even though early detection saves lives, and even as colorectal cancer is now the number one cancer killer for Americans under 50.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login